Greenwich Lifesciences Ownership

GLSI
 Stock
  

USD 9.82  0.27  2.68%   

Some institutional investors establish a significant position in stocks such as Greenwich Lifesciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Greenwich Lifesciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please check Risk vs Return Analysis.
  
Greenwich Lifesciences Debt to Equity Ratio is most likely to increase slightly in the upcoming years. The last year's value of Debt to Equity Ratio was reported at 0.014.
The market capitalization of Greenwich Lifesciences is $123.92 Million. Greenwich Lifesciences retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 83.26 (percent) of Greenwich Lifesciences outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Greenwich Stock Ownership Analysis

About 83.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.46. Greenwich Lifesciences had not issued any dividends in recent years. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To learn more about Greenwich Lifesciences call the company at 832 819 3232 or check out https://greenwichlifesciences.com.
Besides selling stocks to institutional investors, Greenwich Lifesciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Greenwich Lifesciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Greenwich Lifesciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Greenwich Lifesciences Quarterly Share Based Compensation

224,503

About 83.0% of Greenwich Lifesciences are currently held by insiders. Unlike Greenwich Lifesciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Greenwich Lifesciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Greenwich Lifesciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Greenwich Lifesciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Greenwich Lifesciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Greenwich Lifesciences specific information freely available to individual and institutional investors to make a timely investment decision.
12th of July 2022
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
View
11th of July 2022
Other Events
View
22nd of June 2022
Unclassified Corporate Event
View
15th of December 2021
Submission of Matters to a Vote of Security Holders
View

Greenwich Lifesciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Greenwich Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Greenwich Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Greenwich Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Greenwich Lifesciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now

   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
128.3 M
Return On Assets
-0.16
Return On Equity
-0.26
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.